- Recursion (RXRX, Financial) partners with HealthVerity to enhance clinical trial capabilities with real-world data.
- Access to de-identified data covering 340 million U.S. lives to be integrated into Recursion OS platform.
- Partnership aims to streamline development, reduce costs, and optimize therapeutic development.
Recursion Pharmaceuticals, Inc. (RXRX), a leading TechBio company, has announced a strategic partnership with HealthVerity, leveraging their real-world data to enhance clinical trial analytics. The collaboration will provide Recursion access to de-identified data covering over 340 million lives in the United States, which will be integrated into its advanced data science and machine learning platform, the Recursion OS.
This partnership is poised to improve clinical trial design, deepen patient population insights, and boost trial feasibility assessments. By utilizing HealthVerity's comprehensive healthcare data ecosystem, Recursion aims to enhance its AI-driven approaches to predict patient responses and optimize study designs while ensuring regulatory compliance and maintaining patient privacy.
The integration of HealthVerity's real-world data into Recursion's platforms is expected to streamline clinical development processes, reduce associated costs, and expedite the development of novel therapeutics. This move aligns with Recursion's broader strategy of using computational tools to industrialize drug development, potentially reducing the time and cost required to bring new therapies to market.
With the majority of the industry’s efforts focused on optimizing clinical trials, Recursion’s initiative with HealthVerity marks a significant step in transforming how clinical development is conceived and executed. The partnership emphasizes a commitment to data-driven decision-making that enhances trial design, recruitment efficiency, and compliance with HIPAA and privacy standards.
